Ingrid Atteryd Heiman

Filings by Ingrid Atteryd Heiman span 2 companies, the busiest being Redwood Pharma and Redwood Pharma AB. We count 3 filings; the first trade dates from 20 June 2017 and the latest from 1 October 2019.

In open-market terms, that means 2 purchases worth €169.3M on one side and 1 sale worth €5,548 on the other. The net balance comes to €169.3M on the buying side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. So far in 2019, the count stands at no purchases and 1 sale.

The newest entry dates from 1 October 2019: an open-market sale of €5,548, in Redwood Pharma AB. The most recent open-market purchase was published on 25 April 2018, 3,118 days ago. Most trades are made public on the day they happen. The regulation allows three business days to notify a trade (MAR article 19). Every figure here comes from the filings published by Finansinspektionen and describes the past, not future prices; it is not investment advice.